FTC Challenges Payments to Delay Generics

Deal to keep generic drug off the market is anti-competitive, regulators say
By Clay Dillow,  Newser Staff
Posted Feb 3, 2009 9:25 AM CST
FTC Challenges Payments to Delay Generics
Generic pharmaceuticals can undercut their name-brand competitors by 90%, prompting some brand-name drug-makers to participate in anti-competitive practices, the FTC claims.   (Getty Images)

(Newser) – The Federal Trade Commission, pledging to oppose “pay-for-delay” agreements, filed suit against a brand-name testosterone-replacement drug manufacturer for paying three competitors to delay introductions of generic versions, the Washington Post reports. Nearly half of settlements between brand-name drug-makers and their generic counterparts in 2006 and 2007 resulted in such arrangements, which the FTC claims violate antitrust laws and create unfair monopolies.
(Read more Solvay Pharmaceuticals stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.

X